|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We used methylation specific polymerase chain reaction to analyze the MGMT promoter methylation status in 100 tumor DNA of Saudi DLBCL patients receiving multi drug regimens.
|
16047061 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As an example, the methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter is a specific predictive biomarker of tumor responsiveness to chemotherapy with alkylating agents.
|
20384628 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic studies showed O-6-methylguanine-DNA methyltransferase (MGMT) methylation, wild type IDH1, and the absence of 1p/19q loss of heterozygosity (LOH) in the tumor genes.
|
20102524 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Signals of activity in cohort 1 (n = 27) included partial (n = 6) and complete (n = 1) response, including in O<sup>6</sup>-methylguanine-DNA methyltransferase unmethylated and bevacizumab-refractory tumors.
|
29683790 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor had no expression of the O -methylguanine methyltransferase (MGMT) gene due to promoter methylation.
|
23042021 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mean total MGMT level varied between tumor types: 554 +/- 404 fmol/mg protein (+/-SD) for prostate cancer, 87.4 +/- 40.3 fmol/mg protein for CNS tumors, and 244 +/- 181 fmol/mg protein for colorectal cancer.
|
20068091 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a steep dose response curve, with lower activity at 66 mg/kg temozolomide and with tumor regressions at 22 and 44 mg/kg restricted to models with low MGMT expression.
|
23335050 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ERCC1 and MGMT were absent in 81% and 46% of tumors analyzed, respectively, suggesting potential benefit from platinum and alkylating agents.
|
26123645 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that deltaMGMT-transduced marrow cells can improve the therapeutic index of BG and BCNU by selectively repopulating the marrow and providing significant marrow tolerance to this combination, allowing intensive therapy of a BCNU-resistant tumor.
|
10223735 |
1999 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Examination of 20 cases whose histological data for recurrent tumors were available revealed that malignant progression occurred in all of the tumors with p14(ARF) methylation but less frequently (50%) in the lesions with MGMT methylation.
|
17493032 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our major findings are a) methylation status of any single gene was largely independent of methylation status of other genes; b) the rates of methylation of p16 and APC and the mean Methylation Index (MI), a reflection of the overall methylation status, were significantly higher in ever smokers than in never smokers; c) the mean MI of tumors arising in former smokers was significantly lower than the mean of current smokers; d) the methylation rates of APC, CDH13 and RARbeta were significantly higher in adenocarcinomas than in squamous cell carcinomas; e) methylation rates of MGMT and GSTP1 were significantly higher in the USA and Australian cases than in those from Japan and Taiwan; and (f) no significant gender-related differences in methylation patterns were noted.
|
12455028 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant correlation was seen between grade III tumor and loss of expression of ERalpha, ERbeta, PR (all P < .0001), and MGMT (P = .04), whereas loss of expression of p16 was associated with grades I and II tumors (P < .001).
|
16867861 |
2006 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
NSCLC patients with brain metastasis treated by brain surgery followed by radiotherapy may have a higher chance of relapse when the tumour has methylation of the MGMT promoter region.
|
22262716 |
2012 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To examine the proportion of patients in NRG Oncology/RTOG 0424 with MGMT promoter methylation and its association with survival outcomes.
|
29955793 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MGMT methylation and loss of expression were significantly more frequent in advanced thymic epithelial tumors (III/IV) than in early tumors (I/II).
|
24388682 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aims of this study were: i) to correlate tumor MGMT expression and patient and tumor characteristics in malignant breast carcinomas treated with induction chemotherapy including cyclophosphamide (CPM) and ii) to study the predictive and prognostic values of tumor MGMT gene expression.
|
12370764 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The abnormal function of O(6)-methylguanine-DNA methyltransferase (MGMT) is reported to be associated with the occurrence of various tumors and malignant tumor progression.
|
22196440 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, 16 samples were assessed for the presence of hypermethylated DNA for tumor suppressor genes: MGMT, P16, RAR-beta2, RASSF1A, and APC.
|
17108212 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To investigate the role of epigenetic changes in the promoter region of tumor-suppressor genes in the retinoblastoma genome and to study the disruption of expression of O6-methylguanine-DNA Methyltransferase (MGMT) due to aberrant methylation and its association with retinoblastoma.
|
11980845 |
2002 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The odds of having strong CD8 and CD68 reactivity was significantly less in MGMT methylated tumors.
|
29302887 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
MGMT promoter hypermethylation was present significantly more often in tumors with a G to A mutation in p53 (9 of 14; 64%) than in tumors with other types of p53 mutations (11 of 41; 27%; P = 0.02) or in tumors with wild-type p53 (7 of 37; 18%; P = 0.006).
|
11719438 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited.
|
26476729 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The statuses of TP53 and expression of TP53 and O(6)-methylguanine DNA-methyltransferase (MGMT) were determined retrospectively in tumor tissue from enrolled patients.
|
24248532 |
2014 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Tumor and serum samples were screened for MGMT promoter methylation.
|
23443801 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Of 47 patients with MGMT methylation results, 36 (65%) had methylated tumors.
|
23553268 |
2013 |